Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hybridoma Technology01:31

Hybridoma Technology

15.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

High-throughput measurements of protein domain functions using magnetic separation.

Nature protocols·2026
Same author

Harmonizing standards and resources for the medical genome.

Nature·2026
Same author

Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphoma.

HemaSphere·2026
Same author

MHC Attention: Identifying HLA-E presented cancer antigens through deep learning and high-throughput screening.

bioRxiv : the preprint server for biology·2026
Same author

Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Identification and functional characterization of plasma exosomal miR-618 as a novel biomarker in recurrent depressive disorder.

Frontiers in pharmacology·2026

相关实验视频

Updated: Sep 19, 2025

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.1K

机器引导的双重目标蛋白质工程用于除免疫和治疗功能.

Eric Wolfsberg1, Jean-Sebastien Paul2, Josh Tycko3

  • 1Department of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.

Cell systems
|June 4, 2025
PubMed
概括

这项研究引入了一种工作流程,通过优化蛋白质域来减少对细胞和基因疗法的免疫反应. 它使用机器学习来最大限度地减少免疫性,提高治疗的安全性和有效性.

关键词:
蛋白质设计 蛋白质设计合成生物学 合成生物学

更多相关视频

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.1K
Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

7.9K

相关实验视频

Last Updated: Sep 19, 2025

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.1K
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.1K
Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

7.9K

科学领域:

  • 生物技术是生物技术.
  • 免疫学 免疫学 免疫学
  • 基因组医学是基因组医学.

背景情况:

  • 细胞和基因疗法可以触发由于非人类蛋白质的免疫反应.
  • 修改的人类蛋白质域可能仍然含有免疫性,这对治疗开发构成了挑战.

研究的目的:

  • 开发一个模块化工作流程,以优化蛋白质功能并最大限度地减少治疗蛋白质中的免疫性.
  • 通过减少抗治疗免疫反应,创造更安全,更有效的细胞和基因疗法.

主要方法:

  • 利用机器学习模型来预测蛋白质功能和-MHC呈现.
  • 应用工作流程,从转录激活和RNA结合域中去除免疫性MHC II表位.
  • 开发了去免疫的指阵列,用于向基因上调.

主要成果:

  • 成功地从蛋白质域中移除了潜在的免疫原性MHC II表位.
  • 产生的小分子可控制的转录因子与人类衍生的DNA结合域.
  • 使用免疫解除的指阵列,证明了乌托芬 (UTRN) 和SCN1A基因的上调.

结论:

  • 提出的模块化工作流提供了一种提高细胞和基因疗法的安全性和有效性的策略.
  • 机器学习用于免疫性预测和蛋白质工程的整合是下一代治疗方法的一个有希望的方法.